Publication analysis · Module 9
MOTS-c and exercise: keep the human and animal experiments separate
This paper combines human exercise measurements with experimental MOTS-c administration in animals. Changes in endogenous MOTS-c after human exercise and animal performance findings are distinct results. The human component is not a trial demonstrating that injected MOTS-c reproduces exercise benefits in people.
Original publication
MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis
DOI 10.1038/s41467-020-20790-0 · PMID 33473109 · Citation pending verification
Educational information for healthcare professionals and the general public. Not individual medical advice, diagnosis, treatment, or a recommendation to use a compound.
Study and main findings
This paper combines human exercise measurements with experimental MOTS-c administration in animals. Changes in endogenous MOTS-c after human exercise and animal performance findings are distinct results. The human component is not a trial demonstrating that injected MOTS-c reproduces exercise benefits in people.
Interpretation
The distinction is a useful model for reading translational research. A paper can contain human observations and still leave the therapeutic question at a preclinical stage. Identify the intervention separately in each experiment before interpreting the title as a clinical claim.
Limits of the conclusion
The findings provide a biological rationale for further investigation. They do not by themselves establish a human treatment indication, an optimal regimen, a long-term safety profile, or a benefit in human longevity. An analogue is also a different intervention and needs its own evidence.
How to read it critically
In a figure-by-figure review, label species, administered substance or physiological exposure, comparator, and endpoint. Retain uncertainty even when several results support a coherent mechanism. This approach preserves the scientific value of the paper while avoiding the substitution of a mechanistic narrative for a clinical trial.
Original publication
References
Bibliographic sources shown for transparency. Citation verification pending; no citation is marked verified.
Related resources
Publication analysis · Module 9
EVOKE: mechanism and clinical progression
The phase 3 evoke and evoke+ trials studied oral semaglutide in early symptomatic Alzheimer’s disease. The primary endpoint measured clinical progression using CDR-SB at 104 weeks. Semaglutide did not slow that progression compared with placebo.
Publication analysis · Module 1
STEP 1: what a weight-management trial can establish
STEP 1 randomized 1,961 adults with overweight or obesity, without diabetes, to subcutaneous semaglutide or placebo with lifestyle support for 68 weeks. Mean weight change was −14.9% versus −2.4%. Gastrointestinal events led to discontinuation in 4.5% versus 0.8%. The study was funded by Novo Nordisk.
Publication analysis · Module 3
SURMOUNT-1: interpreting a multigroup obesity trial
SURMOUNT-1 randomized 2,539 adults with overweight or obesity, excluding diabetes, to three weekly tirzepatide groups or placebo for 72 weeks. Mean weight changes were −15.0%, −19.5%, and −20.9% in the 5-, 10-, and 15-mg study groups, respectively, versus −3.1% with placebo. These amounts identify trial groups, not an administration recommendation.